SCHEMBL4910192

SCHEMBL4910192

COCCCCC1(CNC(=O)[C@H]2C[C@@H](C(=O)NCCC(C)C)CN(C(=O)OC(C)(C)C)C2)c2ccccc2Oc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 5/20 0.54
MAPT P10636 2/20 0.35
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NAMPT P43490 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
APAF1 O14727 1/20 0.33
USP2 O75604 1/20 0.33
NSD2 O96028 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
XBP1 P17861 1/20 0.33
CASP1 P29466 1/20 0.33
BLM P54132 1/20 0.33
CASP7 P55210 1/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4910054 1.00 REN (0.54) RENMAPTLMNAHTTSMN1; SMN2
SCHEMBL4910052 1.00 REN (0.54) RENMAPTLMNAHTTSMN1; SMN2
SCHEMBL4907695 0.95 REN (0.54) RENMAPTNAMPTKDM4EALDH1A1
SCHEMBL4907699 0.95 REN (0.54) RENMAPTNAMPTKDM4EALDH1A1
SCHEMBL4912112 0.95 REN (0.54) RENMAPTNAMPTKDM4EALDH1A1
SCHEMBL14089230 0.95 REN (0.54) RENMAPTNAMPTKDM4EALDH1A1
SCHEMBL4902242 0.93 REN (0.55) RENMAPTLMNANAMPTKDM4E
SCHEMBL4903306 0.93 REN (0.55) RENMAPTLMNANAMPTKDM4E
SCHEMBL4902246 0.93 REN (0.55) RENMAPTLMNANAMPTKDM4E
SCHEMBL4909887 0.92 REN (0.55) RENMAPTNAMPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors BAESCHLIN DANIEL KASPAR 2008-08-14 US disclosed
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors BAESCHLIN DANIEL KASPAR 2008-08-14 US disclosed
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors BAESCHLIN DANIEL KASPAR 2008-08-14 US disclosed
WO-2006117183-A1 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors REN, ACE, AGTR1 REN 1/4885MAPT 1706/4885LMNA 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.